₹ 0.2 Cr
Volume transacted
0.4 K
stocks traded
Last Updated time: 25 Jul 9.00 AM
Procter & Gamble Health Ltd
NSE: PGHL
PE
40.5
Last updated : 25 Jul 9.00 AM
The P/E Ratio of Procter & Gamble Health Ltd is 40.5 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Procter & Gamble Health Ltd changed from 39.9 to 38 over 4 quarters. This represents a CAGR of -4.76% a1#The Latest Trading Price of Procter & Gamble Health Ltd is ₹ 5250 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Procter & Gamble Health Ltd changed from ₹ 6751 crore to ₹ 8713 crore over 4 quarters. This represents a CAGR of 29.06% a1#The Revenue of Procter & Gamble Health Ltd changed from ₹ 270.17 crore to ₹ 254.75 crore over 8 quarters. This represents a CAGR of -2.90% a1#The EBITDA of Procter & Gamble Health Ltd changed from ₹ 71.12 crore to ₹ 69.71 crore over 8 quarters. This represents a CAGR of -1.00% a1#The Net Pr of Procter & Gamble Health Ltd changed from ₹ 51.16 crore to ₹ 46.56 crore over 8 quarters. This represents a CAGR of -4.60% a1#The Dividend Payout of Procter & Gamble Health Ltd changed from 150.27 % to 44.49 % over 4 quarters. This represents a CAGR of -70.39% a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
June 2020 | 39.9 |
June 2021 | 52.5 |
June 2022 | 36.1 |
June 2023 | 38 |
Market Cap
₹ 8,716 Cr
EPS
₹ 128.9
P/E Ratio (TTM) *
40.5
P/B Ratio (TTM) *
10.8
Day’s High
₹ 5304.85
Day’s Low
₹ 5200.0
DTE *
0.0
ROE *
28.1
52 Week High
₹ 5640.0
52 Week Low
₹ 4640.3
ROCE *
38.1
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
Procter & Gamble Health Ltd
NSE: PGHL
PRICE
₹ 5250.6
23.35 (0.45%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
1
S
Weakness
1
W
Opportunity
0
O
Threats
0
T
Market Value
₹ 8,677
Asset Value
₹ 821
9.6 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Procter & Gamble Health Ltd | 40 | 8,677 |
Sun Pharmaceuticals Industries Ltd | 38 | 388,632 |
Cipla Ltd | 28 | 121,443 |
Divis Laboratories Ltd | 75 | 120,718 |
Zydus Lifesciences Ltd | 30 | 118,680 |
Dr Reddys Laboratories Ltd | 20 | 113,730 |
Earnings
₹214 Cr
40.5 X
PE Ratio
Market Cap
₹8677Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹214 Cr
40.5 X
PE Ratio
Market Cap
₹8677Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
June 2020 | 6752 |
June 2021 | 9286 |
June 2022 | 6951 |
June 2023 | 8714 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Dec '22 | 270 |
Jun '22 | 301 |
Sep '22 | 315 |
Dec '23 | 326 |
Mar '23 | 307 |
Jun '23 | 311 |
Sep '23 | 315 |
Dec '24 | 255 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Dec '22 | 71 |
Jun '22 | 94 |
Sep '22 | 113 |
Dec '23 | 85 |
Mar '23 | 51 |
Jun '23 | 95 |
Sep '23 | 107 |
Dec '24 | 70 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Dec '22 | 51 |
Jun '22 | 64 |
Sep '22 | 77 |
Dec '23 | 59 |
Mar '23 | 30 |
Jun '23 | 66 |
Sep '23 | 72 |
Dec '24 | 47 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
June 2020 | 150 |
June 2021 | 122 |
June 2022 | 45 |
June 2023 | 44 |
* All values are a in %
Procter & Gamble Health Limited (formerly Merck Limited), is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. The company offers prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs. The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients. Merck Ltd was incorporated in the year 1967 as E Merck (India) Ltd. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. The company started their operations as a manufacturer of pharmaceutical specialties and over the years, they have diversified their product range to include basic drugs, fine and industrial chemicals, and diagnostics. In the year 1981, the company became a public limited company they were the first in the Merck group. In December 2000, the company acquired the Livogen brand from Glaxo India for a consideration of Rs 8 crore. They entered into a co-marketing tie-up with the domestic Pharma Company Kopran for a new anti-inflammatory drug Rofecoxib, in the country. They launched new drug under the brand name of 'Acrobat', while Kopran launched the product under the brand name of 'Ziflam'. In the year 2002, the company launched Anti-diabetic molecule, namely 'Glimepiride' in the market. They changed their name from E Merck (India) Ltd to Merck Ltd with effect from March 27, 2002 in order to create one strong international Merck brand and to develop a uniform international image. In the year 2004, the company sold their Taloja undertaking to Biochem Pharmaceutical Industries Ltd for a consideration of Rs 100 million. In addition, the Pharma section of the company started a new unit, namely Consumer Health Care to market medicines for common ailments. In the same year, the company formed a Public Charitable Trust known as 'Merck India Charitable Trust' with the main object of rendering financial assistance to children from the poorer section of society, to pursue primary and secondary education. In the year 2005, the company increased the production capacity of Bulk Drugs by 18 tonnes to 318 tonnes. They launched a new product, namely Pedimune, which is a formulation to improve the immunity level of Children. In the year 2006, the company expanded the production capacity of Bulk Drugs by 33 tonnes to 351 tonnes. In April 2006, the Life Science and Analytics (excluding Bulk Drugs) Business (LS&A business) of the Division was sold to Merck Specialities Pvt Ltd. All the assets and rights on the manufacturing and distribution facilities were transferred to Merck Specialities Pvt Ltd. In the year 2007, the company increased the production capacity of Injection/ Nasal Drops by 24 kilolitres to 427 kiloliters. The Pharmaceuticals segments launched Olmighty Tablets, Evion Forte Tablets, Polybion Complete Syrup, Met Neurobion Injection, Livogen CZ Tablets and Nasivion Care Drops. In the year 2008, the company expanded the production capacity of Bulk Drugs by 128 tonnes to 479 tonnes, Injection/ Nasal Drops by 13 kiloliters to 440 kiloliters and Tablets/ Capsules by 40 million Nos to 400 million Nos. In addition, they commissioned the project for the substantial expansion of the production capacity of their patented molecule, Oxynex ST. This plant is a 100% export-oriented unit and having a capacity to produce around 150 tonnes per year. In March 2016, the Health Ministry banned 344 fixed drug combinations through a gazette notification, based on the recommendation of its expert committee. Two drugs produced by the Company were impacted by this ban order. Pharmaceutical companies including the company challenged the order before the Hon'ble Delhi High Court and the Court was pleased to set aside the government notification. The Government may challenge the said decision of the Hon'ble Delhi High Court before Hon'ble Supreme court. Any adverse decision by the higher court or further addition to this list of banned drugs could impact the growth of the pharmaceutical companies. The Company has received a demand notice frorfi National Pharmaceutical Pricing Authority (NPPA) demanding a sum of Rs116.8 million plus interest Rs157.8 million alleging overcharging of price of the formulation Polybion L 100 ML syrup during the period from May 2006 to June 2009. The Company has challenged the said orders by way of a writ petition. In a separate proceedings filed by Cfadel Pharmaceuticals Private Limited, the manufacturer of the said drug, Hon'ble Kolkata High Court granted temporary stay against the demand notice subject to a sum of Rs22.5 million being deposited with NPPA, which the Company has made. The Company has been legally advised it has a good defendable case. The Company has challenged the said orders and will defend itself vigorously, however, any adverse orders by the courts may have material impact on the profits of the Company. During the year 2016, the Company introduced a new drug Lipigo (Rosuvastatin) which received enthusiatic market response. During the Financial Year 2018-19, Company launched Whisper Choice Aloe Vera. The Company launched flagship brand 'Neurobion Forte' in FY 2019-20. It launched the 'New Livogen Iron' and 'Multivitamin Tonic', a comprehensive iron syrup. Polybion launched the New Polybion Active Syrup, a superior B Complex Syrup enriched with Lysine in a sugar free tasty mango flavour base. During the year 2019-20, the shareholders of the Company vide their resolution dated June 12, 2018, had approved the execution of a business transfer agreement (BTA) with Merck Life Science Private Limited (MLSPL) to sell, lease or transfer certain businesses of the Company comprising biopharma, performance materials and life science segments (BPL business) to MLSPL , for an overall consideration of Rs 105,200 lakhs on a slump sale basis, which completed in November 30, 2018. And subsequent to this, Company's main business was changed to manufacturing and marketing of pharmaceuticals.
Procter & Gamble Health announces board meeting date
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 21...
Read more
28 Jun 202411:17
Procter & Gamble Health to declare Quarterly Result
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 2 ...
Read more
28 Mar 202410:29
Board of Procter & Gamble Health recommends interim dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meetin...
Read more
07 Feb 202411:47
Board of Procter & Gamble Health recommends special dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meetin...
Read more
07 Feb 202411:47
Procter & Gamble Health to table results
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 6 ...
Read more
13 Jan 202411:55
Procter & Gamble Health to hold board meeting
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 3 ...
Read more
28 Sep 202312:01
FAQs for PE of Procter & Gamble Health Ltd
What is Procter & Gamble Health Ltd current share price?
What is Procter & Gamble Health Ltd's market cap?
What are Procter & Gamble Health Ltd's total net assets?
Is Procter & Gamble Health Ltd making a profit or loss?
Unlimited trading at just
Rs. 199